WaveMan
WaveMan · Company
BGM · Bgm Group Ltd.
> Search tickers & screens ⌘K
LIVE
← All companies

BGM BGM (BGM) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001779578
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
8
13F, latest reported quarter

BGM insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for BGM Group Ltd. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Foreign private issuer: its insiders are exempt from SEC Form 4 and report in the home market, so their buys and sells do not appear here.

Insider
Filed
Shares
Value
Since filing

no insider purchases or sales on record

0 transactions on record
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
8 funds bought in last quarter
below 89% of Pharma & Biotech
Revenue
+51.1% year over year
more than 77% of Pharma & Biotech
Margin
-52.6% net margin
below 51% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
0.2% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
below 94% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch BGM

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

Who owns BGM: institutional holders (13F)

13F holdings, latest reported quarter
GEODE CAPITAL MANAGEMENT, LLC
98,472 sh
$36.2K
XTX Topco Ltd
63,089 sh
$23.2K
UBS Group AG
57,646 sh
$21.2K
JANE STREET GROUP, LLC
57,227 sh
$21.0K
SUSQUEHANNA INTERNATIONAL GROUP, LLP
32,067 sh
$11.8K

Congress trades in BGM

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

BGM planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 8 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

BGM financials

Revenue growth
+51.1%
XBRL, annual
Net margin
-52.6%
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-092024-092023-092022-09
Revenue$37.9M$25.1M$46.5M$64.9M
Gross profit$6.3M$4.1M$1.8M$6.2M
Operating income-$12.6M-$563.8K-$2.6M$2.1M
Net income-$19.9M-$1.4M-$7.8M$1.1M
EPS (diluted)-0.18-0.20-1.080.15
Operating cash flow-$2.4M$544.2K$312.2K$12.7M
Cash$9.8M$9.8M$7.5M$14.3M
Dividends paidn/an/a$1.8Mn/a
SEC XBRL, fiscal years, as known on 2026-10-28

BGM Stock Sonar score 3/7 axes

Find similar shapesCompare

BGM ranks highest on risk and compliance (91st percentile) and growth (77th), and lowest on institutional and government (11th), among Pharma & Biotech peers.

Growth
77
Inputs
  • Revenue growth, YoY+51.1% · 77 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
11
Inputs
  • Funds adding, latest quarter8 · 11 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
91
Inputs
  • Short interest, % of float+0.2% · 91 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
4 not measured: Profitability, Financial health, Insider conviction, US patents
  • Profitability needs 2 of 4 inputs, 0 present: fewer than four consecutive quarters of net income; fewer than four consecutive quarters of operating income
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies